Posts

RA Capital Launches Rare Disease Company Oak Hill Bio onto Nasdaq via SPAC

on

PureTech Spins Off Celea with $180M Funding to Advance IPF Drug Deupirfenidone into Phase 3

on

Serapha Bio takes flight from Boundless merger with $230M and gene-editing prospect from China

on

Boundless Bio agrees to reverse merger with Serapha Bio in $230M gene‑editing deal

on

RA, Forbion and Sanofi Ventures appear to back new eye drug from Korea – 2026 update

on

Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management

on

AnaptysBio Halts Phase 2 Ulcerative Colitis Trial; Lyell Immunopharma Secures CAR-T Rights

on

Elevara Raises $70M to Advance Novel Rheumatoid Arthritis Treatment Targeting Synovial Fibroblasts

on

Sanofi Partners with EVOQ Therapeutics to Advance NanoDisc-Based Autoimmune Therapies

on

Sparrow Pharmaceuticals Raises $95M Series B for Midstage Diabetes Study

on

J&J Halts Phase 2a Rheumatoid Arthritis Program for Imaavy (Nipocalimab) after Lackluster Results

on

Sandoz Challenges Amgen in Antitrust Lawsuit to Launch Enbrel Biosimilar in the U.S.

on

Bambusa Therapeutics Secures $90M Series A Funding to Advance Bispecific Antibodies for I&I Disorders

on

AnaptysBio's Rosnilimab Shows Promising Results in Phase 2b Rheumatoid Arthritis Trial, Driving Stock Surge

on

AnaptysBio's Rosnilimab Shows Promising Results in Phase 2b Rheumatoid Arthritis Trial

on